000 03560nam  2200373zi 4500
0019.934143
003CaOODSP
00520240222102334
006m     o  d f      
007cr mn|||||||||
008240219e201303  onca    o    f000 0 eng d
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
045 |ay0y1
0861 |aH14-582/2013E-PDF
24500|aFinal audit report : |baudit of the transfer payment to the Canadian Agency for Drugs and Technologies in Health.
24617|aAudit of the transfer payment to the CADTH : |bfinal audit report
264 1|a[Ottawa] : |bHealth Canada = Santé Canada, |cMarch 2013.
300 |a1 online resource (i, 21 pages) : |bcolour illustration + |emanagement reponse and action plan (1 page)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Rapport de vérification final : vérification du paiement de transfert à l'Agence canadienne des médicaments et des technologies de la santé.
500 |aCover title.
520 |a"The proper management of government funds is an important aspect of grant and contribution oversight. This audit focussed on a conditional grant for $87.5M which was paid over a fiveyear period ending March 31, 2013 to the Canadian Agency for Drugs and Technologies in Health (the recipient). The recipient has received the funds from Health Canada to provide information and advice to health care system decision makers about the effectiveness and efficiency of drugs, medical devices and other health technologies. As the expiration of the conditional grant approaches, the Strategic Policy Branch will be moving to a five-year contribution agreement. Health Canada's conditional grant accounts for approximately 78 percent of the recipient's funding; provinces and territories account for the remaining 22 percent. The objectives of the audit are to determine whether the Strategic Policy Branch has put in place an effective management control framework for the oversight and management of the funding agreement and whether the Canadian Agency for Drugs and Technologies in Health has complied with the terms and conditions of the funding agreement. The audit involved the conduct of sufficient and appropriate procedures and the gathering of evidence to support the audit conclusion. …"--Executive summary, page i.
61020|aCanadian Agency for Drugs and Technologies in Health|xFinance|xAuditing.
61010|aCanada. |bHealth Canada|xAuditing.
7101 |aCanada. |bHealth Canada. |bPortfolio Audit and Accountability Bureau, |eissuing body.
77508|tRapport de vérification final : |w(CaOODSP)9.934322
85640|qPDF|s149 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H14-582-2013-eng.pdf|z(final audit report)
85640|qPDF|s14 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H14-582-2013-1-eng.pdf|z(management reponse and action plan)
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/corporate/about-health-canada/reports-publications/audit-reports/2013/final-audit-report-audit-transfer-payment-canadian-agency-drugs-technologies-health.html|z(final audit report)
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/corporate/about-health-canada/reports-publications/audit-reports/2013/management-response-action-plan-audit-transfer-payment-canadian-agency-drugs-technologies-health.html|z(management reponse and action plan)